The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood
Open accessAbstract
We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei , 67 isolates of C. lusitaniae , 48 isolates of C. guilliermondii , 10 isolates of C. famata , 10 isolates of C. kefyr , 6 isolates of C. pelliculosa , 5 isolates of C. rugosa , 4 isolates of C. lipolytica , 3 isolates of C. dubliniensis , 3 isolates of C. inconspicua , 2 isolates of C. sake , and 1 isolate each of C. lambica , C. norvegensis , and C. zeylanoides . MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei , C. lusitaniae , C. guilliermondii , C. inconspicua , and C. sake . Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa . Posaconazole and voriconazole were active (MIC, ≤1 μg/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationEpidemiology of nosocomial fungal infections
Fridkin, S. K., & Jarvis, W. R. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.499 · Cited by 782
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 1×
“krusei is best known for its propensity to emerge in settings where fluconazole is used for Candida prophylaxis (1, 23, 49, 50).”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Self-citationKao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Self-citationRees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 1×
“The number of fungal species causing invasive mycoses appears to be increasing steadily (15, 37).”
BackgroundPfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269 · cited 1×
“Clearly, they are rare, and only by tracking BSI isolates of Candida species over time in the context of global surveillance programs can one eventually make such a determination (34).”
BackgroundSelf-citationPfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
Self-citationQuality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., & Rinaldi, M. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3457-3459.2000 · Cited by 211
Self-citationImproved Detection of Amphotericin B-Resistant Isolates of Candida lusitaniae by Etest
Peyron, F., Favel, A., Michel-Nguyen, A., Gilly, M., Regli, P., & Bolmström, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.339-342.2001 · Cited by 87 · cited 4×
“lusitaniae is a species that is frequently mentioned in the literature as being capable of developing resistance to amphotericin B during the course of treatment (2, 14, 23, 26, 28, 29).”
BackgroundInfluentialPfaller, M. A., Messer, S. A., & Hollis, R. J. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90106-6 · Cited by 86 · cited 4×
“lusitaniae is a species that is frequently mentioned in the literature as being capable of developing resistance to amphotericin B during the course of treatment (2, 14, 23, 26, 28, 29).”
BackgroundInfluential
Cited by
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Invasive fungal infections: a review of epidemiology and management options
Enoch, D. A., Ludlam, H. A., & Brown, N. M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46548-0 · Cited by 501
Yarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential
Groenewald, M., Boekhout, T., Neuvéglise, C., Gaillardin, C., van Dijck, P. W. M., & Wyss, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.770386 · Cited by 498
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Hollis, R. J., & Jones, R. N.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2003-01
- Volume
- 41
- Issue
- 1
- Pages
- 78-83
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2166718919
- Cited by
- 165
- References
- 14
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.